STAT November 11, 2024
Elaine Chen

Emraclidine was a centerpiece of the company’s purchase of Cerevel Therapeutics

AbbVie said Monday that its experimental treatment for schizophrenia failed to significantly help patients in two trials, a blow to the company, which got the drug through its recent...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Mergers & Acquisitions / JV, Pharma, Pharma / Biotech, Trends
2025 Pharma Forecast: Four Pivotal Trends Revolutionizing Market Access Strategies
Christophe Weber, veteran Takeda CEO, to retire next year
Walmart To Expand Same-Day Prescription Delivery Nationwide
Podcast: Market Failures, Lessons or Opportunities? 1/30/25
FDA warns GLP-1 compounder over safety rules

Share This Article